文献速递免疫规划卫生政策与健康促进

供者疫苗接种用于造血细胞移植:系统综述与未来展望

Vaccinating donors for hematopoietic cell transplantation: A systematic review and future perspectives.
PubMed 文献 · Vaccine · 2018-09-06

该系统综述评估了异基因造血细胞移植(Allo-HCT)供者疫苗接种策略的免疫原性、有效性和安全性。检索Medline、Cochrane图书馆和Scopus等数据库后,52篇全文中有5篇符合有效性和免疫原性纳入标准、1篇提供安全性数据。纳入研究结果不一致且方法学质量普遍欠佳,无研究报道供者接种对受者的长期获益,因此目前不能推荐对所有供者接种疫苗。

要点

  • 纳入的5项有效性和免疫原性研究结果不一致,方法学质量普遍欠佳。
  • 多数研究(n=3)评估了多种疫苗,但并非所有HCT常用疫苗均被研究。
  • 无研究报道供者接种对HCT受者的长期获益,仅1项研究报告安全性数据。

核心结论

  • 鉴于纳入研究方法学质量欠佳且有效性存疑,目前不能推荐对所有供者进行疫苗接种。
  • 需要开展前瞻性高质量供者疫苗试验。

研究设计与样本

  • 系统综述,检索Medline、Cochrane对照试验中心注册库、Cochrane系统综述数据库和Scopus,并筛选会议摘要及手工检索综述和指南文章。
  • 共审查52篇全文,其中5篇符合有效性和免疫原性试验的纳入/排除标准,1篇纳入安全性数据。
  • 采用Jadad评分评估纳入研究质量。

主要发现

  • 纳入研究结果不一致,且研究普遍方法学质量欠佳。
  • 多数纳入研究(n=3)评估了不止一种疫苗,但并非所有HCT常用疫苗均被研究。
  • 无研究报告供者接种对HCT受者的长期获益。
  • 仅1项研究报告了供者接种的安全性数据。

临床怎么用

  • 基于现有证据,供者疫苗接种不能推荐用于所有供者。

局限性

  • 原文述纳入研究方法学质量欠佳(suboptimal methodological quality)。
  • 原文述纳入研究结果不一致(inconsistent)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic cell transplantation (Allo-HCT) recipients are at an increased risk of infectious complications, which is a major cause of morbidity and mortality post-transplant. Vaccination of donors is one of the strategies that has been studied to improve immune reconstitution post-transplant, however the efficacy and safety of this strategy is not well reviewed in the literature. In this systematic review we sought to evaluate the current strategies of donor vaccination along with their immunogenicity, effectiveness and safety. Utilizing strict selection criteria with defined MeSH terminology, an electronic search was conducted from the following databases: Medline, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews and Scopus. Abstracts of various professional society meetings were also screened and hand searching of various reviews and guideline articles was carried out. The full text of 52 articles were reviewed, from which 5 articles satisfied the inclusion/exclusion criteria for effectiveness and immunogenicity trials and 1 article was included for safety data. Jadad score was used to assess the quality of included studies. The results of the included studies were inconsistent, and the studies were generally of suboptimal methodological quality. Most of the included studies (n = 3) investigated the use of more than one vaccine, however not all commonly used vaccines in HCT were investigated. None of the studies reported any long-term benefits for HCT recipients of vaccinated donors. Only one study reported safety data of using vaccination in donors. Given the suboptimal quality of the studies, and questionable effectiveness, donor vaccination cannot be recommended for all. Prospective high-quality vaccine trials in HCT donors are needed.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Muhsen IN, Aljurf M, Wingard JR, et al. Vaccinating donors for hematopoietic cell transplantation: A systematic review and future perspectives. Vaccine. 2018. PMID: 30195488. doi:10.1016/j.vaccine.2018.08.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。